Results 1 to 10 of about 109,033 (289)

Sex Differences in Recovery and Device Replacement After Left Ventricular Assist Device Implantation as Destination Therapy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background The relevance of sex and preimplant factors for clinical outcomes among patients with left ventricular assist devices intended for destination therapy is unclear.
Lisa‐Marie Maukel, Gerdi Weidner, Jan Beyersmann, Heike Spaderna   +3 more
doaj   +4 more sources

Mechanical circulatory support for destination therapy [PDF]

Swiss Medical Weekly, 2016
Patients with chronic heart failure who are not eligible for heart transplant and whose life expectancy depends mainly on the heart disease may benefit from mechanical circulatory support.
Piergiorgio Tozzi, Roger Hullin
doaj   +5 more sources

Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right [PDF]

European Cardiology Review, 2020
For almost half a century, cardiac transplant has been the only long-term treatment for patients with end-stage heart failure. Implantable left ventricular assist devices (LVADs) have emerged as a new treatment option for advanced heart failure as ...
Antoni Bayes-Genis, Christian Muñoz-Guijosa, Evelyn Santiago-Vacas, Santiago Montero, Cosme García-García, Pau Codina, Julio Núñez, Josep Lupón   +7 more
doaj   +4 more sources

Commentary: Cost-Effectiveness of Left Ventricular Assist Devices as Destination Therapy in the United Kingdom [PDF]

Frontiers in Cardiovascular Medicine, 2022
Priyansh Faldu, Kamal Sharma, Shaival Sharma, Smeet Ramani, Nain Dadhania, Ashwati Konat   +5 more
doaj   +4 more sources

Left Ventricular Assist Device as a Destination Therapy: Current Situation and the Importance of Patient Selection [PDF]

Life, 2023
Advanced heart failure is a growing problem for which the best treatment is cardiac transplantation. However, the shortage of donors’ hearts made left ventricular assist devices as destination therapy (DT-LVAD) a highly recommended alternative: they ...
María Melendo-Viu, David Dobarro, Sergio Raposeiras Roubin, Carmen Llamas Pernas, Candela Moliz Cordón, Miriam Vazquez Lamas, Miguel Piñón Esteban, Maria Ángela Varela Martínez, Emad Abu Assi, Rafael Pita Romero, Juan José Legarra Calderón, Andrés Íñiguez Romo   +11 more
doaj   +2 more sources

Perceptions of Bereaved Caregivers and Clinicians About End‐of‐Life Care for Patients With Destination Therapy Left Ventricular Assist Devices [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Patients with left ventricular assist devices (LVADs) implanted as destination therapy may receive suboptimal preparation for and care at the end of life, but there is limited understanding of the reasons for these shortcomings.
Sarah Chuzi, Adeboye Ogunseitan, Kenzie A. Cameron, Kathleen Grady, Lauren Schulze, Jane E. Wilcox   +5 more
doaj   +2 more sources

Heart failure in Poland: Left ventricular assist device destination therapy and other challenges of interventional cardiology and cardiac surgery [PDF]

Cardiology Journal, 2020
Patients with severe heart failure (HF), who are not eligible for cardiac transplantation and receive optimal medical management, based mainly on the use of pharmacological treatment and devices such as resynchronization therapy (implantable cardioverter-
Mariusz Kuśmierczyk, Jacek Różański, Michał Zembala, Dariusz Dudek, Wojciech Braksator, Tomasz Grodzicki, Piotr Hoffman, Jerzy Sadowski, Marcin Gruchała, Jacek Legutko, Piotr Siondalski, Karol Wierzbicki, Bogusław Kapelak, Grzegorz Opolski, Andrzej Juraszek, Katarzyna Bondaryk, Jacek Walczak, Izabela Pieniążek, Maciej Grys, Piotr Przygodzki   +19 more
doaj   +2 more sources

Outcomes of Left Ventricular Assist Devices as Destination Therapy: A Systematic Review with Meta-Analysis [PDF]

Life
Background: Heart failure (HF) is a chronic condition that significantly affects morbidity and mortality. For patients with end-stage HF who are not candidates for heart transplantation, left ventricular assist devices (LVADs) provide mechanical ...
Emad Ali Al Khoufi
doaj   +2 more sources

Risk Factors for Development of Stroke in Patients With Continuous-Flow Left Ventricular Assist Device Support as Destination Therapy [PDF]

Texas Heart Institute Journal
Background: Continuous-flow left ventricular assist devices (LVADs) are increasingly used as destination therapy. Although postimplantation stroke rates have been described in the context of bridge-to-transplant or mixed cohorts, stroke development is ...
Ioana B. Florea, MD, MPHS, Nadia H. Bakir, MD, Meghan O. Kelly, MD, Joel D. Schilling, MD, PhD, Gregory A. Ewald, MD, Akinobu Itoh, MD, PhD, Marc R. Moon, MD, Spencer J. Melby, MD, Ralph J. Damiano, Jr, MD, Kunal D. Kotkar, MD, Muhammad F. Masood, MD   +10 more
doaj   +2 more sources

Cost‐effectiveness of left ventricular assist devices as destination therapy in the United Kingdom [PDF]

ESC Heart Failure, 2021
Aims Continuous‐flow left ventricular assist devices (LVADs) as destination therapy (DT) are a recommended treatment by National Institute for Health and Care Excellence England for end‐stage heart failure patients ineligible for cardiac transplantation.
Stephan Schueler, Scott C. Silvestry, William G. Cotts, Mark S. Slaughter, Wayne C. Levy, Richard K. Cheng, Jennifer A. Beckman, Jonas Villinger, Eleni Ismyrloglou, Stelios I. Tsintzos, Claudius Mahr   +10 more
doaj   +2 more sources